Pharmacokinetics and Pharmacodynamics of Melagatran, a Novel Synthetic LMW Thrombin Inhibitor, in Patients with Acute DVT

Summary

Forty-eight patients with acute proximal deep vein thrombosis (DVT) were randomised to intravenous infusions for 4 to 6 days with melagatran, a novel synthetic low molecular weight thrombin inhibitor, or unfractionated heparin adjusted by the activated partial thromboplastin time (APTT). The aim of the study was to investigate the pharmacokinetics, pharmacodynamics and the safety of melagatran therapy at three different doses. Steady-state plasma concentrations were rapidly achieved and maintained throughout the infusion period. The mean plasma concentrations in the low, medium and high dose groups were 0.17, 0.31 and 0.53 μmol/l, respectively. The prolongation of APTT was stable during the melagatran infusions and correlated to the plasma concentration. Phlebographically verified regression of thrombus size measured as decrease in Marder score was seen after 4 to 6 days in 8 of 12 patients, 6 of 12 patients and 5 of 11 patients in the low, medium and high dose groups of melagatran and in 5 of the heparin-treated patients. In the low dose group with melagatran, thrombus extension was seen in one patient. At the dose levels studied, melagatran was well tolerated with no clinically significant bleeding problems, suggesting that melagatran could safely be given to patients suffering from DVT.

• References

• 1 Girard P, Hauuy MP, Musset D, Simonneau G, Petipretz P. Acute inferior vena cava thrombosis. Early results of heparin therapy. Chest 1989; 95: 284-91.
• 2 Walker MG, Shaw JW, Thomson GJL, Cumming JGR, Thomas ML. Sub-cutaneous calcium heparin versus intravenous sodium heparin treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial. Br Med J 1987; 294: 1189-92.
• 3 Holmström M, Lindmarker P, Granqvist S, Johnsson H, Lockner D. A 6-month venographic follow-up in 164 patients with acute deep venous thrombosis. Thromb Haemost 1997; 78 (02) 803-7.
• 4 O’shaughnessy AM, Fitzgerald DE. Natural history of proximal deep vein thrombosis assessed by duplex ultrasound. Int Angiol 1997; 16: 45-9.
• 5 Hirsh J. Heparin. N Engl J Med 1986; 315: 1109-14.
• 6 Schiele F, Lindgaerde F, Eriksson H, Bassand JP, Wallmark A, Hansson PO, Grollier G, Sjo M, Moi M, Camez A, Smyth V, Walker M. For the international multicentre Hirudin Study Group. Subcutaneous recombinant Hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomised trial. Thromb Haemost 1997; 77: 834-8.
• 7 Bounameaux H, Ehringer H, Hulting J, Rasche H, Rapold HJ, Zultak M. and the ADVENT Trial. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (Napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep vein thrombosis. Results of the European Multicenter ADVENT Trial. Thromb Haemost 1997; 78: 997-1002.
• 8 Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Persson S, Karlsson O, Nilsson A, örensen H. Effects of melagatran, a new low molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110-8.
• 9 Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78: 1286-92.
• 10 Mattsson C, Björkman JA, Ulvinge JC. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinol Proteol 1997; 11: 121-8.
• 11 Carlsson S, Nilsson A, Börjesson I, Halvarsson M, Eriksson B, Mattsson C, Gustafsson D. Melagatran, a novel low molecular thrombin inhibitor examined in several deep venous thrombosis models in rat. Thromb and Haemost 1997; Suppl (Abstract) 497.
• 12 Eriksson I B, Carlsson S, Halvarsson M, Risberg B, Mattsson C. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 1997; 78: 1404-7.
• 13 Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, Edward N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep venous thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-29.
• 14 Weitz I J, Hudoda M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombine III but is susceptible to inactivation by antithrombin II-independent inhibitors. J Clin Invest 1990; 86: 385-91.
• 15 Agnelli G, Renga C, Weitz JL, Nenci GG, Hirsh J. Sustained antithrombotic ability of hirudin after its plasma clearance: Comparison with heparin. Blood 1992; 80: 960-5.
• 16 Doyle DJ, Turpie AGG, Hirsh J. et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. Ann Intern Med 1987; 107: 441-5.
• 17 Hull RD, Raskob GE, Pineo GF. et al. Subcutaneous low-molecular -weight heparin compared with continous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
• 18 Lagerstedt I C, Olsson CG, Fagher BO, Öquist BO, Albrechtsson U. Need for long-term anticoagulant treatment in symtomatic calf vein thrombosis. Lancet 1985; 1: 515-8.
• 19 Hull RD, Delmore TJ, Genton E, Hirsh J, Gent M, Sackett DL, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8.
• 20 Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Larfars G, Leijd B, Linder O, Loogna E, Walter H, Viering S, Hjorth M. Boberg J; the Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-8.
• 21 Parent F, Bridey F, Dreyfus M, Musset D, Gimon G, Duroux P, Meyer D, Simonneau G. Treatment of severe venous thromboembolism with intravenous Hirudin (HBW023): An open pilot study. Thromb Haemost 1993; 70: 386-8.
• 22 Schiele F, Vuillermenot A, Kramarz Ph, Kieffer Y, Soria J, Soria C, Camez A, Mirshahi MC, Bassand JP. A pilot study of subcutaneous recombinant Hirudin (HBW023) in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 558-62.
• 23 Ginsburg JS, Nurmohamed MT, Gent M, Mackinnon B, Stevens P, Weitz J, Maraganore J, Hirsh J. Effects on thrombin generation of single injections of hirulog in patients with calf vein thrombosis. Thromb Haemost 1994; 72: 523-5.
• 24 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.